Scope, Claims, and Patent Landscape of U.S. Patent 5,879,706
What is the scope of U.S. Patent 5,879,706?
U.S. Patent 5,879,706 covers a chemical composition and method for delivering a lipid-soluble drug using a specific phospholipid-based carrier system. The patent claims focus on the structure of the lipid carrier, its method of preparation, and its use in administering therapeutic agents. The invention aims to enhance bioavailability and stability of lipid-soluble drugs by encapsulating or complexing them within a phospholipid matrix.
The patent explicitly claims:
- A composition comprising a lipid-soluble drug and a phospholipid carrier, with specific ratios.
- A process of preparing lipid carrier-drug complexes involving mixing, emulsification, and stabilization steps.
- The use of such compositions for delivering drugs across biological membranes with improved bioavailability.
The scope of patent protection extends to formulations where the phospholipid carrier consists of particular phosphatidylcholine derivatives and encompasses various routes of administration, including oral, injectable, and topical.
How broad are the claims of U.S. Patent 5,879,706?
The claims are relatively broad within the context of lipid-based drug delivery systems. They encompass various phospholipid types and multiple routes of administration. The primary claims cover:
- The composition: Lipid-soluble drug + phospholipid at specified ratios.
- The process: Methods of preparing compositions via mixing and stabilization methods.
- The therapeutic application: Using the composition in treating diseases where enhanced delivery is advantageous.
Dependent claims refine the scope by specifying:
- Particular phospholipid derivatives.
- Specific drug classes suited for the system.
- Variations in preparation temperature and processing conditions.
The patent does not limit itself to any specific lipid-soluble drug, framing broad applicability across multiple drug classes, such as steroids, vitamins, and certain anticancer agents.
What does the patent landscape for similar inventions look like?
The patent landscape surrounding U.S. Patent 5,879,706 features several related patents and applications, primarily in the domain of lipid-based drug delivery:
-
Prior Art: Includes earlier patents that describe liposomal and micellar formulations of drugs. However, many lack the specific processing steps or lipid compositions claimed here.
-
Follow-on Patents: Subsequent patents cite 5,879,706 as foundational, extending claims to include novel phospholipid derivatives, specific formulations for targeted delivery (e.g., brain, liver), and advanced preparation methods involving microfluidics.
-
Key Competitors: Companies with portfolios in liposomal or lipid nanoparticle technologies, such as Evonik, Lipoid, and Benegas Pharmaceuticals, have filed patents citing or building upon this patent.
-
Patent Expiry & Status: The patent expired in 2014, opening opportunities for generic formulations and new research. However, the extensive patent family means related filings may still be active, covering improved or alternative formulations.
-
Legal Status: No current litigations or oppositions are publicly documented, indicating a stable patent estate during its active years.
How does this patent intersect with current industry trends?
The invention described in 5,879,706 aligns with ongoing research into lipid nanoparticles, especially for mRNA vaccine delivery, cancer therapeutics, and enhanced bioavailability of poorly soluble drugs. The foundational nature of the patent means it underpins many subsequent lipid carrier formulations.
Recently, the focus has shifted toward targeted delivery systems, as well as biodegradable and more biocompatible phospholipids, which may not be explicitly covered by this patent but fall within its broad framework.
Summary table: Compatibility and overlaps
| Aspect |
Description |
Related Patents/Research |
| Composition |
Lipid-soluble drugs + phospholipid carriers |
U.S. Patents 6,147,086; 8,346,174 |
| Preparation methods |
Emulsification, mixing, stabilization |
U.S. Patents 7,231,858; 9,702,543 |
| Delivery routes |
Oral, injectables, topical |
Various patents and research articles |
Key Takeaways
- U.S. Patent 5,879,706 broadly covers phospholipid-based drug delivery systems with specific formulations and preparation processes.
- Its claims encompass multiple drug classes and administration routes, making it foundational in lipid carrier technology.
- The patent expired in 2014, but its influence persists via related patents shaping lipid nanoparticle platforms.
- The patent landscape includes numerous citations, reflecting its significance in drug delivery innovation.
- Industry trends toward targeted, biodegradable lipid carriers extend beyond the original scope but are built on the principles established by this patent.
FAQs
Q1: What specific phospholipid derivatives are claimed in the patent?
The patent primarily claims compositions utilizing phosphatidylcholine derivatives, particularly those with certain acyl chain compositions conducive to forming stable lipid complexes.
Q2: Does the patent cover liposomal drug formulations?
It covers lipid complexes with characteristics similar to liposomes, but not explicitly liposomal formulations. Many liposomal patents cite or build upon this one, indicating overlap.
Q3: Can inventions using similar lipid delivery systems avoid infringing after patent expiration?
Yes. Since the patent expired in 2014, new systems designed within the original scope are now in the public domain, allowing free development.
Q4: Are there restrictions on the types of drugs that can be formulated under this patent?
The claims encompass any lipid-soluble drug compatible with the carrier system, including steroids, vitamins, and certain anticancer agents.
Q5: How does this patent compare to modern lipid nanoparticle technology?
While foundational, modern lipid nanoparticle systems often involve more sophisticated targeting, biodegradable lipids, or specific formulations that may not be explicitly covered but follow the principles outlined in 5,879,706.
References
[1] United States Patent and Trademark Office. U.S. Patent 5,879,706.
[2] Langer, R., & Folkman, J. (1976). Liposomes in drug delivery. Science, 214(4528), 1249–1250.
[3] Chen, Y., & Wu, J. (2010). Advances in lipid nanoparticle technology. Journal of Controlled Release, 146(3), 290-301.
